Squamous Non-small-cell Lung Cancer Clinical Trials

8 recruitingLast updated: June 17, 2026

There are 8 actively recruiting squamous non-small-cell lung cancer clinical trials across 22 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Madrid, Spain, Milan, Italy, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Squamous Non-small-cell Lung Cancer Trials at a Glance

8 actively recruiting trials for squamous non-small-cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Madrid, Milan, and Barcelona. Lead sponsors running squamous non-small-cell lung cancer studies include Alentis Therapeutics AG, AstraZeneca, and Allist Pharmaceuticals, Inc..

Browse squamous non-small-cell lung cancer trials by phase

Treatments under study

About Squamous Non-small-cell Lung Cancer Clinical Trials

Looking for clinical trials for Squamous Non-small-cell Lung Cancer? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Squamous Non-small-cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Squamous Non-small-cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Squamous Non-small-cell Lung Cancer
Merck Sharp & Dohme LLC180 enrolled51 locationsNCT07221474
Recruiting
Phase 2

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Non-small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-Small Cell Lung Cancer (Stage III)+5 more
Genelux Corporation142 enrolled15 locationsNCT06463665
Recruiting
Phase 1Phase 2

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Breast CancerOvarian CancerEndometrial Cancer+2 more
AstraZeneca460 enrolled67 locationsNCT05123482
Recruiting
Phase 1

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Advanced Gastric CancerMetastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung Cancer+4 more
BeiGene514 enrolled17 locationsNCT06585488
Recruiting
Phase 1Phase 2

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Colorectal, CancerUrothelial CarcinomaSquamous Non-small-cell Lung Cancer+2 more
Alentis Therapeutics AG180 enrolled28 locationsNCT07169734
Recruiting
Phase 1Phase 2

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Esophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaSquamous Non-small-cell Lung Cancer+1 more
Alentis Therapeutics AG170 enrolled38 locationsNCT06747585
Recruiting
Phase 1Phase 2

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Triple-Negative Breast CancerAdvanced Solid TumorHead and Neck Squamous Cell Carcinoma+7 more
Volastra Therapeutics, Inc.200 enrolled14 locationsNCT05902988
Recruiting
Phase 3

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung CancerMetastatic Non-Squamous Non-Small Cell Lung Cancer
Allist Pharmaceuticals, Inc.392 enrolled37 locationsNCT06416410